CLINICAL TRIAL

Long-term Follow-up for Prostate Cancer

1 Prior Treatment
Metastatic
Recurrent
Waitlist Available · Any Age · Male · Duarte, CA

This study is evaluating whether a long-term follow-up works in patients with prostate cancer after surgery.

See full description

About the trial for Prostate Cancer

Eligible Conditions
Prostate Cancer · Cancer Survivors · Prostatic Neoplasms

Treatment Groups

This trial involves 2 different treatments. Long-term Follow-up is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Questionnaire Administration
OTHER
Long-term Follow-up
OTHER
Educational Intervention
OTHER
Laboratory Biomarker Analysis
OTHER
Quality-of-Life Assessment
OTHER
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for male patients of any age. You must have received 1 prior treatment for Prostate Cancer or one of the other 2 conditions listed above. There are 8 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Diagnosis of prostate cancer
No prior treatment of prostate cancer with radiation or chemotherapy
No history of other urologic cancer (e.g., bladder cancer, renal cell carcinoma) in addition to prostate cancer
Note: Patients who develop recurrence while participating in the Prostate Cancer Survivorship Clinic will be referred back to their urologist and may resume participation in the Survivorship Clinic when deemed appropriate by their treating physician
Treated with a definitive surgical procedure at City of Hope
At least one year post surgical treatment for prostate cancer
No history of recurrent, progressive, or metastatic disease
Currently stable disease or no evidence of disease
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 10 years
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 10 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 10 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Long-term Follow-up will improve 3 primary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to 10 years.

HRQL assessed using Expanded Prostate Cancer Index Composite
UP TO 10 YEARS
Linear mixed effects models can be used to estimate long-term trends and examine the effects of baseline and concomitant factors on these trends.
UP TO 10 YEARS
Incidence rates of the study end-points
UP TO 10 YEARS
Incidence rates of the study end-points that may be associated with original diagnosis or treatment received, and delineation of temporal changes in serial measurements and their relationship to time-invariant characteristics such as original diagnosis, race, and education and time-varying characteristics such as age and body mass index will be estimated. Incidence rates may be compared with national standards adjusted for key demographic variables and between patient subgroups.
UP TO 10 YEARS
HRQL assessed using Sexual Health Inventory for Men
UP TO 10 YEARS
Linear mixed effects models can be used to estimate long-term trends and examine the effects of baseline and concomitant factors on these trends.
UP TO 10 YEARS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of prostate cancer?

What are the signs of prostate cancer? Prostatic enlargement is a sign of prostate cancer. Other signs include increased urinary frequency and urgency, sudden change in frequency or urgency of urination, unexplained blood in the urine and increased blood in the men's semen.

Anonymous Patient Answer

Can prostate cancer be cured?

Men who are diagnosed with localized [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s, where clinical risk stratification and Gleason score of 7 (with PSA ≤20 ng/mL) have similar outcomes, may be considered for active surveillance, watchful waiting, or active treatments such as radical prostatectomy or radiation therapy.

Anonymous Patient Answer

What are common treatments for prostate cancer?

Many patients who develop symptomatic prostate cancer are not receiving the recommended treatment by their physicians, but rather will typically be receiving treatments that are frequently prescribed in accordance with practice guidelines. While the most common treatment for prostate cancer is surgery, the most common alternative treatment is active surveillance. These data support the ongoing need for improved practice patterns for prostate cancer care at the individual patient level and at the population level.

Anonymous Patient Answer

How many people get prostate cancer a year in the United States?

About 1 in 2 men aged 50-59 years diagnosed in the past year were diagnosed with prostate cancer. The number is nearly equal among White and Black men and approximately one-third of men in his fifties (age range 50-59 years) were diagnosed with it. However, more African-American men were diagnosed with benign prostatic hyperplasia than any other racial group.

Anonymous Patient Answer

What is prostate cancer?

Prostate cancer is a serious and life-threatening disease. The five-year survival rate with radical prostatectomy in men with prostate cancer is 85 to 90%. Even among men with localized disease, the five-year survival rate after prostatectomy (without adjuvant therapies) is 55%. In an attempt to reduce prostatectomy side effects and the risks of adjuvant therapy, men without symptoms, on digital rectal examination or have PSA values of<20 ng/mL should undergo a prostate biopsy to assess for prostate cancer. In a subsequent procedure, a biopsy guided by suspicion, a needle biopsy or open biopsy is performed, and if this shows suspicious findings, radical prostatectomy is recommended.

Anonymous Patient Answer

What causes prostate cancer?

[prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) does not have a clear cause. It is more likely that it develops because of a problem with cells in the prostate that has affected the patient's health and/or their environment. At a basic level, prostate cancer happens because cells in the prostate have problematic changes to their DNA.

Anonymous Patient Answer

What is long-term follow-up?

Long-term followup and medical imaging for PCa survivors show that only 2 of 8 patients had PCa surveillance after 10 years. However, in all patients there are signs of late effects, such as LUTS, osteopenia and osteoporosis, increased cardiovascular risk, and hormonal alterations. Thus, the long-term followup and medical imaging shows that PCa survivors are exposed to significant risks. Therefore, it would be prudent to reconsider the role of PCa surveillance and to develop a comprehensive management program for survivors.

Anonymous Patient Answer

Have there been other clinical trials involving long-term follow-up?

No studies have been reported examining the long-term effects of long-term follow-up (or “watch-and-wait”) of patients with BPH. Because the rate of tumor progression and symptoms are the same for all prostate cancer patients and no studies have shown differences between them, we believe that other randomized trials using an active surveillance strategy would be challenging to conduct.

Anonymous Patient Answer

What are the latest developments in long-term follow-up for therapeutic use?

New developments have permitted surveillance of patients to permit us to confirm the good prognosis of prostate cancer with long-term clinical controls before recommending the end of follow-up.

Anonymous Patient Answer

Does prostate cancer run in families?

Results from a recent clinical trial suggest that prostate cancer may have a familial component and are consistent with a multifactorial etiomy for this disease.

Anonymous Patient Answer

What are the common side effects of long-term follow-up?

The most important side effects of active surveillance and watchful waiting are a decrease in testosterone and an increase in prostate-specific antigen. Prostate-specific antigen levels are often not associated with actual tumor progression; thus, they do not seem to be a useful marker for progression prevention. The most frequently observed side effects are erectile dysfunction, urgency, ejaculation disorders and urinary continence disturbances. Other common side effects include fatigue, dysprosia, depression, headaches, dizziness and insomnia. No correlation is found between side effects and gender or age.

Anonymous Patient Answer

What are the chances of developing prostate cancer?

Findings from a recent study indicates that 1 in 20 Caucasians of ages 50 to 70 are likely to develop prostate cancer in the next 15 years. The prevalence of prostate cancer among black men is substantially higher than among white and Hispanic men.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.